Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS29P7 is a processed pseudogene in the human genome, formally approved by the HUGO Gene Nomenclature Committee (HGNC ID: HGNC:36594)[3][9]. It is related to the **ribosomal protein S29 gene (RPS29)** but does not encode a functional protein and has no direct biological activity. Pseudogenes such as RPS29P7 are remnants of protein-coding genes but typically lack function due to disabling mutations or absence of regulatory elements[3][6][9]. RPS29P7 is not implicated as a therapeutic target and does not serve any known biomarker or disease role. Many pseudogenes exist for ribosomal proteins, reflecting their evolutionary history, but RPS29P7 does not produce functional protein nor is it relevant for drug development or clinical purposes[3][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein S29 pseudogene 7 (RPS29P7).